The stock market uptrend has hit some early headwind, hurt by earnings sell-offs for top stocks like Broadcom (AVGO), CrowdStrike (CRWD) and Ciena (CIEN). But what looked like a sure distribution day Thursday for the Nasdaq composite turned into another win for the bulls a
The Federal Communications Commission has run three days of bidding in the "AWS-3" reauction and, so far, there are no real signs that Elon Musk's SpaceX is involved, analysts say. But telecom stocks AT&T (T), Verizon Communications (VZ) and T-Mobile (TMUS) may not be out
By Medha Singh and Twesha Dikshit June 5 Wall Street's main indexes fell on Friday as stronger-than-expected jobs data pushed Treasury yields higher and reinforced hawkish policy bets, while chipmakers slid after a recent rally. Nonfarm payrolls rose by 172,000 jobs in May
Earlier today, in our forensic analysis of the SpaceX IPO, we said that according to BNP estimates, the company's inclusion into the S&P 500 some 6 months after the offering would unlock $13.4 billion worth of inflows. It turns out that that is not going to happen 6 months
Quick Read - CVX has raised its dividend for 39 straight years, with 2025 operating cash flow covering the $12.75B payout nearly 3 times. - In 2020's cash flow collapse, Chevron still paid $9.7B in dividends, backed by a debt-to-equity ratio of just 0.25. - Chevron hit record...<
Two firms raised Hinge Health’s price targets to $80 and $63 after reporting improved profitability and operational momentum. Citizens raised its price target for Hinge Health Inc. (HNGE) to $80 from $65, citing accelerating top-line growth and expanding profitability marg
Analysts raise price targets after Tango shifts focus to first-line pancreatic cancer therapy, anticipating key data later this year. Leerink increased its price target for Tango Therapeutics (NASDAQ:TNGX) to $55 from $28, maintaining an Outperform rating following first-q
Erasca Inc. (NASDAQ:ERAS) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 11, Erasca Inc. (NASDAQ:ERAS) announced a supply agreement and a clinical trial partnership with Merck The collaboration is aimed at facilitating the
DYN submits Biologics License Application for z-rostudirsen, seeking Priority Review to shorten FDA approval timeline to six months. Dyne Therapeutics (NASDAQ:DYN) submitted its Biologics License Application to the FDA for z-rostudirsen, a treatment for Duchenne muscular d
Mineralys Therapeutics reports lorundrostat achieved significant systolic blood pressure reductions in Phase 3 trials ahead of FDA review. Mineralys Therapeutics (NASDAQ:MLYS) announced Phase 3 trial results for lorundrostat, demonstrating placebo-adjusted systolic blood p
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.